2 results
Approved WMOCompleted
To confirm the safety of the Articulinx implant by evaluating device and procedure related adverse events.
Approved WMORecruiting
Primary: To assess the proportion of patients with intervention failure at 12 months after dose reduction, defined as patients who have restarted their initial dose due to (expected) loss of major molecular response.